MedTrace Logo

Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity

NCT03139318 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-07-20

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the toxicity profile of GRID therapy using dose levels of 10Gy, 15 Gy and 20Gy in pediatric osteosarcoma of the extremity.

Conditions

  • Osteosarcoma in Children
  • Radiation Toxicity

Interventions

RADIATION

GRID radiotherapy

Patients will be treated with GRID radiotherapy

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Leslie Harrell, MD · University of Arkansas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
5 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-25
Primary Completion
2018-08-29
Completion
2018-08-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03139318 on ClinicalTrials.gov